A new Memorial Sloan Kettering study evaluating a cell-based immune therapy to treat an aggressive form of leukemia reports that 88 percent of patients responded to the treatment. It is the largest study to date to evaluate this treatment for adult patients with B cell acute lymphoblastic leukemia (ALL), a rapidly progressing form of blood cancer.